Skip to main content
BHVN logo

BHVN · Biohaven Ltd. · Metrics

Track BHVN — free
$12.39 -1.26 (-9.23%) At close · Nov 20 Q4 2021 earnings call transcript
Market Cap
$1.87B
Shares
151.06M
Volume · Nov 20 2.39M Avg daily vol (3M) 3.22M

BHVN metrics

60 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$12.39
Market cap
$1.87B

Price action

23 metrics
Price change (1W)
-10.3%
Price change (30D)
-10.7%
Price change (3M)
-10.5%
Price change (6M)
+31.1%
Price change (YTD)
+9.7%
Price change (1Y)
+28.7%
Trailing year
Price change (5Y)
—
52-week high
$16.95
52-week low
$8.09
Change from 52-week high
-26.9%
Change from 52-week low
+53.2%
Annualized volatility
82.6%
Annualized volatility (3M)
96.6%
Implied volatility (30D)
99.0%
IV rank (1Y)
40.8
IV percentile (1Y)
60.9
Beta
1.3
RSI (14D)
40.6
Price vs SMA 50
-7.7%
Price vs SMA 200
+0.1%
Avg volume (3M)
3.22M
Relative volume
0.7
Average dollar volume
$45.72M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
151.06M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
-25.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-29.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-27

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$524.48M
Net income (TTM)
−$542.68M
Trailing 12 months
Diluted EPS (TTM)
$-3.76
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.65

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+42.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-205.8%
Debt / equity
—
Current ratio
3.1
EBITDA (TTM)
—
Free cash flow (TTM)
−$473.17M
Quick ratio
3.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$103.17M
Latest balance sheet
Cash & equivalents
$95.75M
Total assets
$263.68M
Total debt
$264.29M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$472.53M
Capital expenditures (TTM)
$642,000
R&D (TTM)
$428.44M
SG&A (TTM)
—
Stock compensation (TTM)
$83.03M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
304
13F filer change QoQ
+7
Institutional ownership
93.5%
Conviction holders (share of 13F filers)
2.6%
Crowding (high-turnover and private-fund holders)
42.7%
Private-fund adviser ownership
38.9%
Active holders' share change QoQ
+6.1%
Holder tenure
11.3
Price vs estimated holder cost
-13.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.5%

Short interest

3 metrics
Short interest
9.9%
Latest settlement · 2.9 days to cover
Days to cover
2.9d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1935979 CUSIP G1110E107 13F (30d) 298 filings 272 filers Visit website Investor relations